Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 2/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.41 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 4/20 | 0.40 |
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7900977 | 0.89 | GAK (0.41) | GAKRIPK2COQ8ANLKSLC22A12 | |
| SCHEMBL25606892 | 0.80 | HTR1A (0.44) | SLC22A12MAPKAPK2 | |
| SCHEMBL29924048 | 0.79 | LPL (0.41) | GAKRIPK2SLC22A12CDK8CCNC | |
| SCHEMBL16156637 | 0.79 | LPL (0.41) | GAKRIPK2SLC22A12CDK8CCNC | |
| SCHEMBL16156593 | 0.79 | NR4A2 (0.47) | GAKRIPK2COQ8ANLKCDK8 | |
| SCHEMBL23911086 | 0.77 | LMNA (0.48) | GAKRIPK2COQ8ANLKSLC22A12 | |
| SCHEMBL4396762 | 0.76 | KDM4E (0.39) | GAKMAPKAPK2 | |
| SCHEMBL30074594 | 0.76 | EGFR (0.34) | — | |
| SCHEMBL25606843 | 0.76 | EGFR (0.34) | — | |
| SCHEMBL30728959 | 0.75 | NCF1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989173-B | Imidazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2022184000-A1 | IMIDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-114989173-A | Imidazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| CN-108779115-B | Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2376455-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | GAK 1320/4885RIPK2 599/4885COQ8A 2889/4885 |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | GAK 3340/4885RIPK2 3077/4885COQ8A 3093/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | GAK 3340/4885RIPK2 3077/4885COQ8A 3093/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | GAK 3920/4885RIPK2 3537/4885COQ8A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.